ATE228002T1 - Regulierung von nf-kappa-b aktivität durch proteasome - Google Patents

Regulierung von nf-kappa-b aktivität durch proteasome

Info

Publication number
ATE228002T1
ATE228002T1 AT95914075T AT95914075T ATE228002T1 AT E228002 T1 ATE228002 T1 AT E228002T1 AT 95914075 T AT95914075 T AT 95914075T AT 95914075 T AT95914075 T AT 95914075T AT E228002 T1 ATE228002 T1 AT E228002T1
Authority
AT
Austria
Prior art keywords
activity
proteasomes
kappa
regulation
animal
Prior art date
Application number
AT95914075T
Other languages
English (en)
Inventor
Vito J Palombella
Alfred L Golberg
Thomas P Maniatis
Oliver Rando
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22782682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE228002(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Harvard College filed Critical Harvard College
Application granted granted Critical
Publication of ATE228002T1 publication Critical patent/ATE228002T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detergent Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT95914075T 1994-03-18 1995-03-17 Regulierung von nf-kappa-b aktivität durch proteasome ATE228002T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/210,381 US6660268B1 (en) 1994-03-18 1994-03-18 Proteasome regulation of NF-KB activity
PCT/US1995/003315 WO1995025533A1 (en) 1994-03-18 1995-03-17 PROTEASOME REGULATION OF NF-λB ACTIVITY

Publications (1)

Publication Number Publication Date
ATE228002T1 true ATE228002T1 (de) 2002-12-15

Family

ID=22782682

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914075T ATE228002T1 (de) 1994-03-18 1995-03-17 Regulierung von nf-kappa-b aktivität durch proteasome

Country Status (11)

Country Link
US (2) US6660268B1 (de)
EP (1) EP0750507B2 (de)
JP (1) JPH09510710A (de)
AT (1) ATE228002T1 (de)
CA (1) CA2184727C (de)
DE (1) DE69528888T3 (de)
DK (1) DK0750507T4 (de)
ES (1) ES2182897T5 (de)
PT (1) PT750507E (de)
SI (1) SI0750507T2 (de)
WO (1) WO1995025533A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6838477B2 (en) * 1995-04-12 2005-01-04 President And Fellows Of Harvard College Lactacystin analogs
US5834487A (en) * 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones
ATE240113T1 (de) 1997-02-15 2003-05-15 Millennium Pharm Inc Behandlung von infarkten durch inhibierung von nf-kappab
US6831057B2 (en) 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
US6207412B1 (en) * 1997-11-13 2001-03-27 The Regents Of The University Of California Identification of a G protein-coupled receptor transcriptionally regulated by protein tyrosine kinase signaling in hematopoietic cells
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
EP0982317A1 (de) * 1998-08-26 2000-03-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalente Proteasome Inhibitore
EP0995757A3 (de) * 1998-08-26 2002-05-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalente Proteasom Inhibitore
AU762373B2 (en) 1998-10-20 2003-06-26 Millennium Pharmaceuticals, Inc. Method for monitoring proteasome inhibitor drug action
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US20030165492A1 (en) * 2000-06-08 2003-09-04 Alberto Panerai Method of treatment of alzheimer's disease with a protein extractable from mammalian organs
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
CA2504933C (en) 2002-11-06 2012-10-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating cancer using proteasome inhibitors
EP1581629B1 (de) 2002-12-06 2015-04-01 Millennium Pharmaceuticals, Inc. Verfahren zur identifizierung,beurteilung und behandlung von patienten mit einer proteasomen inhibitions therapie
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CA2558618A1 (en) * 2004-02-06 2005-08-25 The University Of Chicago An anti-inflammatory, cytoprotective factor derivable from a probiotic organism
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
DE102005009784B4 (de) * 2005-03-03 2009-06-18 Technische Universität Darmstadt Peptid-Mimetika, Verfahren zur deren Herstellung, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung als Inhibitoren von Proteasomen und zur Induktion von Apoptose
JP5436860B2 (ja) 2005-11-09 2014-03-05 オニキス セラピューティクス， インク． 酵素阻害のための化合物
NZ573759A (en) 2006-06-19 2012-03-30 Proteolix Inc Peptide epoxyketones for proteasome inhibition
EA018973B1 (ru) 2007-10-04 2013-12-30 Оникс Терапьютикс, Инк. Кристаллические пептидные кето-эпоксидные ингибиторы протеаз и синтез кето-эпоксидов аминокислот
MX2010010348A (es) * 2008-03-26 2010-11-09 Novozymes As Composiciones de enzimas liquidas estabilizadas.
BRPI0919668A2 (pt) 2008-10-21 2018-05-29 Onyx Therapeutics, Inc. terapia de combinação com epóxi-cetonas de peptídeo
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP2498793B1 (de) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib zur verwendung in der metastasensuppression
WO2011087822A1 (en) 2009-12-22 2011-07-21 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
PH12012501719A1 (en) 2010-03-01 2012-11-12 Onyx Therapeutics Inc Compounds for immunoproteasome inhibition
US8697646B2 (en) 2010-04-07 2014-04-15 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
CA2855368A1 (en) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
JP5540340B2 (ja) * 2012-02-29 2014-07-02 独立行政法人理化学研究所 炎症性疾患の判定方法
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
WO2014124134A1 (en) 2013-02-07 2014-08-14 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
CN111879948A (zh) 2013-10-17 2020-11-03 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
CA2985816A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
EP3340999A4 (de) 2015-08-28 2019-06-12 The General Hospital Corporation Agonistische anti-tumor-nekrosefaktorrezeptor-2-antikörper
EP3355914B1 (de) 2015-09-29 2024-03-06 The General Hospital Corporation Eine bcg-haltige zusammensetzung zur cholesterolsenkung.
CA3253342A1 (en) 2016-05-13 2026-03-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
CA3109954A1 (en) 2018-08-20 2020-02-27 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
JP7652690B2 (ja) 2018-11-15 2025-03-27 ザ ジェネラル ホスピタル コーポレイション アゴニスト性腫瘍壊死因子受容体スーパーファミリーポリペプチド
KR20230156016A (ko) * 2020-11-24 2023-11-13 프로게라이프 분절성 프로제로이드 증후군 치료용 화합물
EP4251635A2 (de) * 2020-11-24 2023-10-04 Progelife Verbindungen zur behandlung von umhüllten virusinfektionen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510130A (en) 1983-05-20 1985-04-09 Genetic Diagnostics Corporation Promoting animal and plant growth with leupeptin
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
SE8702550D0 (sv) 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
WO1989008147A1 (en) 1988-03-01 1989-09-08 Whitehead Institute For Biomedical Research ACTIVITION OF NF-kB PRECURSOR
ZA897515B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
JP2701932B2 (ja) 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
HUT62312A (en) 1990-03-05 1993-04-28 Cephalon Inc Process for producing chymotrypsin-like proteases and their inhibitors
WO1992011850A2 (en) 1990-12-28 1992-07-23 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
CA2098702A1 (en) 1990-12-28 1992-06-29 James C. Powers Peptide ketoamides, ketoacids, and ketoesters
WO1992013549A1 (en) * 1991-02-07 1992-08-20 Research Corporation Technologies, Inc. Inhibition of cell proliferation by hydrophobic peptides
EP0504938A3 (en) * 1991-03-22 1993-04-14 Suntory Limited Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient
WO1992020795A1 (en) 1991-05-17 1992-11-26 Cetus Oncology Corporation INHIBITOR OF NF-λB TRANSCRIPTIONAL ACTIVATOR AND USES THEREOF
EP0650368A1 (de) * 1992-06-24 1995-05-03 Cortex Pharmaceuticals, Inc. Verwendung von calpain inhibitoren in der inhibition und behandlung von medizinischen zuständen die mit einer erhöhten calpainaktivität assoziiert sind
DE4311835A1 (de) 1993-04-07 1994-10-13 Boehringer Ingelheim Int Verfahren zur Inhibierung der Transkription von Genen
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
KR970060809A (ko) * 1996-01-19 1997-08-12 김광호 자동응답전화기에서 예약 시각에 등록 음성메세지 전송 방법

Also Published As

Publication number Publication date
JPH09510710A (ja) 1997-10-28
DE69528888T3 (de) 2006-10-05
CA2184727A1 (en) 1995-09-28
SI0750507T1 (en) 2003-04-30
US20040097420A1 (en) 2004-05-20
AU682264B2 (en) 1997-09-25
CA2184727C (en) 2007-08-28
US6660268B1 (en) 2003-12-09
DK0750507T4 (da) 2006-07-03
EP0750507A4 (de) 1999-03-31
EP0750507A1 (de) 1997-01-02
DE69528888D1 (de) 2003-01-02
AU2121595A (en) 1995-10-09
EP0750507B2 (de) 2006-03-01
WO1995025533A1 (en) 1995-09-28
DE69528888T2 (de) 2003-10-23
PT750507E (pt) 2003-04-30
DK0750507T3 (da) 2003-02-17
SI0750507T2 (sl) 2006-08-31
EP0750507B1 (de) 2002-11-20
ES2182897T3 (es) 2003-03-16
ES2182897T5 (es) 2006-10-16

Similar Documents

Publication Publication Date Title
DE69528888D1 (de) Regulierung von nf-kappa-b aktivität durch proteasome
ES2185649T3 (es) Inhibidores de la proliferacion de las celulas germinales y sus utilizaciones.
NO963814L (no) Inhibitor av det 26S proteolytiske kompleks og 20S proteasomet inneholdt deri
DE69734766D1 (de) Hemmstoff und stimulator der proliferation haematopoietischer stammzellen und deren anwendungen
EE04604B1 (et) Raku adhesiooni inhibiitorid
DK1275392T3 (da) Prolactin-hæmmende eller -stimulerende forbindelser til regulering af immunfunktionen
EP0832203A4 (de) Verwendung von neuronalen fötalen zellinien für die transplantationstherapie
MX9703063A (es) Compuestos de ester y acido boronico, su sintesis y usos.
NO975716L (no) Imidazolforbindelser
DK0741694T3 (da) Phenyleddikesyrederivater, fremgangsmåder og mellemprodukter til deres fremstilling og midler indeholdende disse
NO911963L (no) Hydroksaminsyrebaserte kollagenaseinhibitorer.
DE69818445D1 (de) Verwendung von verbindungen die an ein zytoplasmatischen dipeptidase binden zur potenzierung des immunantworts
DE59807973D1 (de) Vorrichtung zum züchten und/oder behandeln von zellen
ATE173392T1 (de) Hemmung des haarwuchses
SE9801287D0 (sv) Incorporation of active substances in carrier matrixes
ATE207964T1 (de) Produktion von ammonium-acrylat
ATE233557T1 (de) Verwendung von konjugiertes linolensäure zur steigerung der aktivität von natural killer- lymphozyten
AU5243493A (en) Regulation of immunoglobin production by interleukin-4 and interleukin-9
ATE227996T1 (de) Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltod
MY112975A (en) Mild refining of triglyceride oil
DK0629242T3 (da) Fremgangsmåde til forøgelse af en plantes tidlige modning og/eller til reduktion af det oplagrede nitratindhold i en plante
DK0914605T3 (da) Molekylemodel for VLA-4-inhibitorer
ATE548033T1 (de) Therapeutisches verfahren zur hemmung von nf- kappa b
ATE405291T1 (de) Mittel zur beeinflussung von hyperaktivierten immunologischen effektorzellen
IL133881A0 (en) Decreased fat adsorption with an anti-lipase antibody

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0750507

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 0750507

Country of ref document: EP